Q-omics provides the consensus-scored ZNF492 profile across patient tissues and cancer cell-line models. ZNF492 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF492 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, ZNF492 RNA expression shows 16,980 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, COAD, and TGCT as cancer lineages where ZNF492 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF492 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF492 survival associations across molecular data types. ZNF492 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF492 RNA expression–survival associations across cancer types. High ZNF492 expression shows unfavorable associations in LUSC and SARC, but favorable associations in UVM, LGG, HNSC and MESO. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF492 RNA expression.
This table summarizes ZNF492 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF492. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF492 shows lower tumor expression in COAD, READ and HNSC and higher tumor expression in UCEC, LIHC and BLCA. The COAD box plot shows higher ZNF492 RNA expression in normal versus tumor tissue (log2 FC = −0.297, t-test p < 0.001).
This table shows molecular features associated with ZNF492 in patient tissues and cancer cell lines. In patient samples, ZNF492 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF492 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
